)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Longeveron (LGVN) investor relations material
Longeveron Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Achieved full enrollment for pivotal phase 2b HLHS trial (ELPIS II), with top-line results expected Q3 2026 and BLA submission targeted for late 2026, pending positive results.
Advanced stem cell pipeline for HLHS, Alzheimer's, and pediatric dilated cardiomyopathy, including FDA IND approval for pediatric DCM and positive regulatory progress for Alzheimer's.
Received FDA Orphan Drug, Fast Track, Rare Pediatric Disease, and RMAT designations for HLHS and Alzheimer's programs.
Discontinued Japan Aging-related Frailty trial to focus resources on core programs.
Ongoing efforts to secure additional financing and strategic partnerships, with substantial doubt about ability to continue as a going concern without new capital.
Financial highlights
Revenue for the first half of 2025 was $0.7M, down 31–32% year-over-year, mainly due to lower demand for clinical trials and contract manufacturing.
Gross profit for the first half of 2025 was $0.4M, a 37% decrease from the prior year.
General and administrative expenses rose 28% to $5.5M; R&D expenses increased 39% to $5.5M, driven by personnel and BLA readiness costs.
Net loss for the first half of 2025 was $10.0M, up 34% year-over-year.
Cash and equivalents stood at $10.2–$10.3M as of June 30, 2025; $5M raised in August public offering, with up to $12.5M more possible from warrants.
Outlook and guidance
Existing cash expected to fund operations into Q1 2026; additional capital required to continue beyond that period.
Operating expenses and capital requirements projected to rise through 2025 and 2026 due to BLA and manufacturing readiness.
BLA filing for HLHS targeted for late 2026, contingent on ELPIS II results; pivotal phase 2 trial for pediatric DCM anticipated to begin in H1 2026, subject to financing.
Seeking partnerships for Alzheimer's program and pursuing non-dilutive funding.
Assess HLHS and DCM market size differences.
HLHS approval impact on DCM regulatory path?
Discuss iPS cell transplant arrhythmia risks.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Longeveron earnings date
Q3 202511 Nov, 2025
Next Longeveron earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Longeveron Inc. is a clinical-stage biotechnology company focused on the development of cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational products are based on allogeneic mesenchymal stem cells (MSCs), which aim to promote tissue repair, reduce inflammation, and enhance immune responses. Longeveron’s research targets indications such as aging-related frailty, cardiovascular diseases, and other chronic conditions. The company is headquartered in Miami, Florida, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage